A Phase 2a Study of Daclatasvir (BMS-790052) in Combination With Peginterferon Alfa-2a(Pegasys) and Ribavirin (Copegus) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.

Trial Profile

A Phase 2a Study of Daclatasvir (BMS-790052) in Combination With Peginterferon Alfa-2a(Pegasys) and Ribavirin (Copegus) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Daclatasvir; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 18 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Primary outcome amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top